PMID- 19761129
OWN - NLM
STAT- MEDLINE
DCOM- 20091222
LR  - 20200929
IS  - 0392-2936 (Print)
IS  - 0392-2936 (Linking)
VI  - 30
IP  - 4
DP  - 2009
TI  - Clinicopathological features of primary fallopian tube carcinoma: a single 
      institution experience.
PG  - 389-95
AB  - PURPOSE OF INVESTIGATION: Primary fallopian tube carcinoma (PFTC) is a rare 
      malignancy with only few data existing on the impact of prognostic factors. 
      METHODS: We retrospectively analyzed 26 patients. Tissue blocks were reviewed and 
      sections were stained for vascular endothelial growth factor (VEGF), matrix 
      metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of 
      metalloproteinases 1 and 2 (TIMP-1, TIMP-2), c-erbB-2, estrogen (ER), and 
      progesterone receptors (PgR). RESULTS: Reactivity for VEGF, ER, PgR, MMP-2, 
      MMP-9, TIMP-1, TIMP-2 and c-erbB-2 was observed in 85%, 46%, 27%, 11.5%, 58%, 0%, 
      23% and 8% of specimens, respectively. None of the markers studied displayed 
      prognostic significance. Regarding clinical prognostic factors, the hazard ratio 
      (HR) for progression and death for patients with tumor residuum > 2 cm was 5.24 
      (p < 0.01) and 11.19 (p < 0.005), respectively. Patients with advanced stage 
      disease had a HR of 12.55 (p < 0.05) for progression, while the HR for death was 
      not found to be statistically significant. CONCLUSION: None of the biomarkers 
      studied seems to influence survival. Early-stage disease and optimal debulking 
      are associated with improved outcome.
FAU - Papadimitriou, C A
AU  - Papadimitriou CA
AD  - Department of Clinical Therapeutics, "Alexandra" Hospital, University of Athens 
      School of Medicine, Greece. chr_papadim@yahoo.gr
FAU - Markaki, S
AU  - Markaki S
FAU - Lianos, E
AU  - Lianos E
FAU - Peitsidis, P
AU  - Peitsidis P
FAU - Vourli, G
AU  - Vourli G
FAU - Nikitas, N
AU  - Nikitas N
FAU - Vlachos, G
AU  - Vlachos G
FAU - Rodolakis, A
AU  - Rodolakis A
FAU - Antsaklis, A
AU  - Antsaklis A
FAU - Dimopoulos, M A
AU  - Dimopoulos MA
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Eur J Gynaecol Oncol
JT  - European journal of gynaecological oncology
JID - 8100357
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma/metabolism/mortality/*pathology
MH  - Disease-Free Survival
MH  - Fallopian Tube Neoplasms/metabolism/mortality/*pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Middle Aged
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/analysis
MH  - Survival Rate
MH  - Tissue Inhibitor of Metalloproteinase-1/metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
EDAT- 2009/09/19 06:00
MHDA- 2009/12/23 06:00
CRDT- 2009/09/19 06:00
PHST- 2009/09/19 06:00 [entrez]
PHST- 2009/09/19 06:00 [pubmed]
PHST- 2009/12/23 06:00 [medline]
PST - ppublish
SO  - Eur J Gynaecol Oncol. 2009;30(4):389-95.